home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Fighting Neuroblastoma

  November, 14 2008 5:14
your information resource in human molecular genetics

A strategy to treat neuroblastoma using the patient's immune cells is published online in Nature Medicine.

Cytotoxic T lymphocytes (CTLs), a type of immune cell that can be directed to fight cancer cells, do not survive long term and have limited antitumour activity within the body. This is partly because the target tumour cells typically lack appropriate co-stimulatory molecules that enhance the effectiveness of the CTLs. Malcolm Brenner and his colleagues have now overcome this limitation by engineering CTLs to express an antigen receptor directed to GD2, a tumor-associated molecule expressed by human neuroblastoma cells. The authors reasoned that these CTLs would receive optimal co-stimulation, enhancing their survival and antitumour activity mediated through the GD2 receptors.

Studying patients with neuroblastoma, the authors find that CTLs expressing the GD2-specific receptor indeed survived longer than control T lymphocytes. Infusion of these engineered cells had no adverse effects and was associated with tumour regression in half of the subjects tested. This leads to the conclusion that CTLs could be a powerful weapon for combating neuroblastoma, and perhaps other tumors, in people.

Author contact:

Malcolm Brenner (Baylor College of Medicine, Houston, TX, USA)
E-mail: mbrenner@bcm.edu

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.